RxDoctor Payments Data

Melissa Hines, APRN

Family · Louisville, KYNPI 1801343140

Payments from drug & device makers

$1,724in general payments, 2019–2025

Across 108 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$427
  • Novo Nordisk$269
  • GSK$208
  • Bayer$127
  • Amgen$122
  • Lilly USA, LLC$88
  • plus $483 from 15 others

What the payments were for

  • Food & beverage$1,71399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,724 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$797
Medicare patients
38
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$22,064
FarxigaDapagliflozin Propanediol17$10,816
OzempicSemaglutide11$9,806
Breo ElliptaFluticasone/Vilanterol11$8,560
SymbicortBudesonide/Formoterol Fumarate12$4,712
Ventolin HfaAlbuterol Sulfate36$4,214
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,767
Albuterol Sulfate HfaAlbuterol Sulfate25$898
Atorvastatin Calcium101$855
Zonisamide13$705
Hydroxyzine Hcl32$553
Rosuvastatin Calcium24$354
Metoprolol Succinate35$348
Amlodipine Besylate95$336
Montelukast Sodium25$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$22,06418 claims
AstraZenecaFarxiga, Symbicort$49$15,52729 claims
Novo NordiskOzempic$269$9,80611 claims
GSKBreo Ellipta$208$8,56011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →